Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 1,099 Shares

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 1,099 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total value of $51,191.42. Following the transaction, the insider owned 143,581 shares of the company’s stock, valued at approximately $6,688,002.98. The trade was a 0.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Dennis Cho also recently made the following trade(s):

• On Monday, December 22nd, Dennis Cho sold 324 shares of Twist Bioscience stock. The shares were sold at an average price of $34.56, for a total transaction of $11,197.44.

Twist Bioscience Trading Up 0.6%

TWST traded up $0.28 during trading on Friday, reaching $47.38. The company had a trading volume of 52,103 shares, compared to its average volume of 1,427,932. The stock has a market cap of $2.90 billion, a P/E ratio of -37.46 and a beta of 2.24. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $54.26. The business has a 50 day simple moving average of $36.54 and a 200-day simple moving average of $31.94. The company has a quick ratio of 3.33, a current ratio of 3.78 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The company had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. Twist Bioscience’s quarterly revenue was up 16.9% compared to the same quarter last year. On average, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on TWST. Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a report on Tuesday. Barclays boosted their target price on Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday. Stephens began coverage on Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price target for the company. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Finally, Evercore ISI lifted their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $45.88.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its holdings in shares of Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after purchasing an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after acquiring an additional 3,181 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after acquiring an additional 37,577 shares during the period. Intech Investment Management LLC raised its holdings in Twist Bioscience by 18.9% in the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after purchasing an additional 4,591 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after purchasing an additional 302 shares in the last quarter.

More Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Company guidance was lifted, with coverage highlighting stronger demand tied to AI-related customers but also noting execution risks; the guidance boost is being read as evidence of improving end-market demand. Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus
• Positive Sentiment: An analyst price target was raised 20% to $48.35, signaling increased bullishness from at least one wall‑street watcher and supporting the recent share-price momentum. TWST price target increased by 20%
• Neutral Sentiment: A recent valuation piece assesses TWST after its run-up and discusses whether the current share price already reflects improved fundamentals and the guidance lift; useful for investors re-evaluating upside vs. valuation risk. Assessing Twist Bioscience Valuation
• Negative Sentiment: CEO Emily Leproust sold 5,001 shares at an average $46.58 (≈0.57% reduction in her stake). Insider sales by the CEO can spook investors even if they are routine. CEO sale filing
• Negative Sentiment: CAO Robert F. Werner reported larger sales: 7,000 shares at an average $45.65 (≈10.65% reduction in one filing) plus an earlier 175-share sale; these are meaningful reductions from a senior finance officer. CAO sale filing
• Negative Sentiment: Other insiders, including SVP Paula Green (1,194 shares) and insider Dennis Cho (1,099 shares), also sold stakes at ~ $46.58, adding to overall insider selling activity this week. SVP sale filing Insider sale filing

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.